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Abstract  
Introduction: Hepatitis B virus and hepatitis C virus are major etiological agents of 
chronic liver disease and hepatocellular carcinoma. Hepatocellular carcinoma is the fifth 
most prevalent tumor type and the third leading cause of cancer-related deaths worldwide. 
Living in military camps and being at a greater risk of injury and hospitalization are 
potential risk factors for acquiring HBV and HCV infections. The risk of sharing utensils 
like razors and toothbrushes, traditional malpractices and unsafe sexual practices may 
contribute for the transmission of HBV and HCV among military personal living in 
military camps which can also serve potential source for the transmission of the viruses to 
the general community at large. 
Objective: The objective of this study was to determine the prevalence and associated risk 
factors of HBV and HCV infection among military personnel at Bahir Dar armed forces 
general hospital, Northwest Ethiopia. 
Methods: A Cross sectional study was conducted from February – May, 2015 among 
military personal at Bahir Dar armed forces general hospital. Based on a systematic 
random sampling technique a total of 403 study participants were included. Hepatitis B 
and C virus infection was determined using HBsAg and anti-HCV antibody test using 
rapid test. Socio demographic data and associated factors were collected through interview 
using structured questionnaire. Data was entered and analyzed using SPSS version 20.The 
P- value < 0.05 was considered statistically significant.   
Results: Of the total of 403 military personnel enrolled, the prevalence of HBsAg and anti 
HCV antibody was 4.2% (17/403) and 0.2% (1/403) respectively. Among the total 
participants positive for viral hepatitis, 4.9% were females and 4.4% were males with the 
age range of 20-52 years. In multivariate linear regression analysis revealed that unsafe 
sexual practice was significantly associated with viral hepatitis infection (AOR= 5.126, 
95% CI 1.306, 20.126 p=0.019).  
Conclusion: The prevalence of hepatitis B and hepatitis C virus infection was intermediate 
and low among military personnel respectively. Routine screening for HBV and HCV in 
military should be implemented and the prevention of the disease should be practiced. 
Key words: HBV, HCV, Military personnel 
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1. Introduction 
1.1. Background 
 Viral hepatitis is an inflammation of the liver due to viral infections and there are groups of 
viruses that affect the liver. The most common types are hepatitis B virus (HBV) and hepatitis C 
virus (HCV) (1). Viral hepatitis is a major health problem worldwide and cause acute and/or 
chronic hepatitis which can leads to the development of extensive liver scarring (cirrhosis), liver 
failure, liver cancer and death (2). 
Hepatitis B virus is first identified in the 1960s by Baruch Samuel Blumberg from an Australian 
Aborigine. Hepatitis B virus (HBV) the Dane particle, is a spherical lipid-containing structure 
with an outer diameter of 42 to 47 nm (3).  It is deoxyribonucleic acid (DNA) virus belonging to 
a family called Hepadnaviridae which can cause acute or chronic infection (4). Hepatitis B virus 
is a circular, partially double-stranded, DNA genome consisting of four major partially over 
lapping open-reading frames that code for four completely different proteins: PreS1, PreS2/S, 
Precore/C, DNA polymerase and the X protein (S, C, X, P). The envelope proteins (PreS1 and 
PreS2/S) are expressed on the surface of hepatitis B surface antigen (HBsAg) positive particles 
and have been shown to be highly immunogenic (5).  Antibodies against HBV proteins are other 
immunological markers of infection, of which anti-Hepatitis B core antigen, Hepatitis B 
envelope antigen and Hepatitis B envelope antibody are also identified shortly after HBSAg, and 
are important markers of past or present HBV infection (6). 
The core protein has a structural function, but may play other important roles in the viral 
lifecycle. Binding of the core protein to HBV RNA/DNA may be involved in 
nuclear/cytoplasmic transfer, viral morphogenesis and packaging as well as down regulation of 
transcription of viral and cellular genes (5). The hepatitis B virus (HBV) is a hepatotropic DNA 
virus that causes acute and chronic hepatitis and hepatocellular carcinoma (7). The direct role for 
HBV in liver cell transformation is controversial. The discovery and demonstration that HBV 
DNA integrates into the DNA of the host hepatocytes was reported to led to HCC (8). 
HBV has been classified into 7 genotypes that is A to G, based on the divergence of entire 
genome sequence and HBV genotypes have distinct geographical distributions. Studies reported 
a correlation of HBV genotypes with HBeAg clearance, liver damage, and the response to IFN 
treatment. It was reported that HBeAg carrier status tends to be longer and the prevalence of 
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HBeAg appears higher in patients with genotype C than with genotype B (9) . HBV carriers with 
genotype B have lower histologic activity scores and genotype C is more prevalence in patients 
with cirrhosis. HBV genotype B is associated with a higher rate of IFN-induced HBeAg 
clearance compared with genotype C. The response of different HBV genotypes to interferon-
alfa treatment is of increasing interest because the benefit of interferon-alfa or its pegylated form 
in combination with other antiviral agents is being explored in the treatment of chronic hepatitis 
B (10). 
The HBV is transmitted through exposure to infectious blood, semen, and other body fluids. 
Hepatitis B virus can also be transmitted from infected mothers to infants or from family 
members to infants in early childhood. Transmission may also occur through unsafe sexual 
intercourse, transfusions of HBV-infected blood and blood products, contaminated injections 
during medical procedures, and sharing of needles and syringes among injecting drug users (11), 
(12) . 
Hepatitis C virus is a small single-stranded ribonucleic acid (RNA) virus that belongs to the 
Flaviviridae family (13) . This virus is mostly transmitted through exposure to infectious blood. 
This may happen through transfusions of HCV-infected blood and blood products, contaminated 
injections during medical procedures, and sharing of needles and syringes among injecting drug 
users. Vertical transmission from infected mother to fetus or transmissions through unsafe sexual 
contact are other possible modes of transmission of the virus. Infection with HCV is a major 
cause of chronic hepatitis around the world. HCV RNA has been unequivocally detected in the 
hepatocytes of liver biopsies of chronically infected patients and chimpanzees, the HCV genome 
has also been suggested to replicate in cells of lymphoid origin and dendritic cells (14). HCV-
mediated liver injury is caused by a diverse and complex array of factors. These factors include 
viral gene products that have direct intracellular and extracellular effects on apoptosis and 
steatosis in hepatocytes, the involvement of non hepatocytes in the fibrotic cascade, and the 
cytotoxic lymphocyte response (both innate and adaptive immune features) to HCV infection.     
Infection with HCV is persistent in most individuals because HCV successfully undermines host 
innate and viral - specific immunity. Chronic HCV infection manifests as variable degrees of 
hepatic inflammation and fibrosis, and as an increased risk of developing cirrhosis and 
hepatocellular carcinoma (HCC) (15) . 
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Hepatitis C can be classified into six genotypes. It is important to note an infected person’s 
speciﬁc genotype as it affects treatment dose, duration, and response. Genotypes 1–3 have a 
worldwide distribution. Genotypes 1a and 1b are the most common, accounting for about 60% of 
global infections. They predominate in Northern, Southern, and Eastern Europe; North America; 
and Japan. Genotype 2 is less frequently represented than genotype 1 and is often associated with 
the risk factor of prior blood transfusion. Type 3 is common in Southeast Asia and is variably 
distributed in different countries. Genotype 4 is principally found in the Middle East, Egypt, 
North and Central Africa. Type 5 is found almost exclusively in South Africa, and genotype 6 is 
distributed throughout Asia (16) . 
Treatment achieves sustained virological response, which means viral eradication, in 55%–60% 
of patients with chronic HCV infection. New triple combinations including HCV protease 
inhibitors have increased the sustained response rates by approximately 30% in difficult to treat, 
naive and treatment experienced patients infected with HCV genotype 1. Future treatment 
options are expected to further improve the sustained virological response rates to over 90% in 
all HCV patients .However, only a small proportion of patients receive treatment and therefore 
the treatment efficacy at the global or community level effectiveness remains poor (17) . 
1.2. Statement of the problem 
Hepatitis B virus (HBV) and hepatitis C virus (HCV) are major etiological agents of chronic 
liver disease and hepatocellular carcinoma (HCC). Hepatocellular carcinoma (HCC) is the fifth 
most prevalent tumor type and the third leading cause of cancer-related deaths worldwide (18). 
Viral hepatitis is now responsible for 1.4 million deaths every year (compared with 1.6 million 
deaths from HIV/AIDS, 1.3 million from tuberculosis and 0.6 million from malaria) (19). 
World Health Organization (WHO) estimates that about two billion people have been infected 
with HBV worldwide and (12) more than 240 million people are chronically infected with the 
virus. About 500 000 - 700 000 people die annually as a result of HBV infection (11) . HBV 
infection has an acute case fatality rate of 0.5 - 1.0%, while 2 - 10% of cases end up in chronic 
infection after 5 years. Premature mortality from chronic liver disease occurs in 15 - 25% of 
chronically infected persons (20) .  
About 150, 000,000 people are chronically infected with HCV worldwide.  More than 350 000 
people are estimated to die from HCV-related liver diseases each year (11) . According to recent 
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estimates, more than 185 million people around the world have been infected with HCV, of 
whom 350 000 die each year (21). The prevalence of hepatitis C infection varies substantially 
around the world. When countries are grouped into Global burden of disease regions, the 
estimated prevalence of HCV infection is highest in Central and East Asia and in the North 
./Africa/Middle East regions. In view of the larger populations in Asia, the South Asia and East 
Asia regions have by far the largest number of persons living with HCV infection (22). The 
prevalence of hepatitis C is even higher in some areas, reaching levels of up to 10% (21).  
The prevalence of HBV infection varies greatly in different regions of the world and it is highly 
endemic in areas such as sub-Saharan Africa, Asia, the Pacific Basin, parts of the Middle East 
and the Amazon Basin (23) . WHO estimates that prevalence of HCV in African is 5.3%, it is 
markedly higher in some areas, particularly Egypt 17.5%. In Kenya and Ethiopia it is estimated 
that more than 60% of chronic liver disease and up to 80% of hepatocellular cancers are due to 
chronic hepatitis B and C viral infections. In Ethiopia, the prevalence of HBV is nearly 10%–
15% and that of HCV is nearly 2%–5% (24). 
The risk of exposure to sexually transmitted diseases (STDs) in Military personnel is 2 to 5 times 
higher when compared with civilian populations (25). Risky sexual behaviors such as sexual 
intercourse with prostitutes,  sex with multiple partners, sex with a partner who has multiple sex 
partners, sex with partners likely to be STD’s carriers, unprotected sex are  among a significant 
risk factors  that expose to STD’s infections, inside and outside the military environment (26). 
As well, multiple partnering is identified to be among the risky behaviors  engaged in by armed 
forces bases on survey conducted in the Nigerian (27).  
Different studies on the prevalence of HBV and HCV have been conducted in different parts of 
Ethiopia, most of them focused on investigating the prevalence among blood donors (28, 29), 
HIV infected individuals (30, 31)  and medical waste handlers (2). There is no data reported 
about the magnitude of HBV and HCV prevalence and associated risk factors among military 
groups in the Amhara National state in particular or the country at large among military 
personnel. Thus, the aim of this study was to determine the prevalence and associated risk factors 
HBV and HCV infection among military personnel attending medical services at Bahir Dar 
armed forces of general Hospital, Northwest Ethiopia. 
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2. Literature review 
The prevalence of both HBV and HCV infection were reported among the different members of 
the community in different countries. Because both of these viruses are transfusion transmissible 
infections (TTIs), screening blood donors for these viruses is the daily practice of many blood 
banks all over the world. The majority of the study results reveled higher prevalence of both 
HBV and HCV infection among peoples living in congregate settings such as the prisons 
compared to the general population. Moreover, some study reports conducted on military 
personnel also showed significantly higher prevalence of HBV and HCV infection compared 
with the general population. For example, Nokhodian et al  reported a 12.9% and 7.4% HBV and 
HCV prevalence respectively among female prisoners in Iran (32). Another study also conducted 
in Iran among 881prisoners showed a 6.9% and 7.7% prevalence of HBV and HCV infection 
respectively. Drug abuse and history of traditional phlebotomy were associated risk factors for 
HBV and history of drug injection was associated with HCV infection  for these study groups 
(33). On the other hand,  reported a 23% and 12% HBV and HCV prevalence among prisoners in 
Nigeria but only 0.07% were co-infected with both HBV and HCV (34) .  A cross sectional study 
conducted in Sudan showed 8.2% HBV infection  among healthy people visited Kassala teaching 
hospital (35). A study conducted in Wolidia, Ethiopia among 270 prison inmates, 10.4% a 
prevalence rate of HBV infection was reported. In this study dental extraction were the major 
risk factors (36). 
 There are also study reports that determined the prevalence of these viruses infection among 
HIV positive individuals. For instance, a cohort study conducted in Nigeria showed  that 11.9% 
HBV  and 4.8% HCV co-infection among HIV infected patients (37).  In the same country, 
another study reported that dual infection by HBV and HCV was found 3.9% but the prevalence 
of HBV and HCV infection among 102 HIV infected patients were 28.4% and 14.7% 
respectively. The study also determined the prevalence of both HBV and HCV prevalence 
among apparently healthy people as control and found much lower prevalence, 6.0% for HBV 
and 0.8% for HCV (38). Another  study conducted in Kenya, Nairobi among 378 HIV positive 
individuals showed a 6% and 1% prevalence of HBV and HCV infection respectively (39). The 
study conducted in Florida in the sexual transmitted infection clinic showed the prevalence of 
HCV infection was 4.7% by the year of 2000. Body tattooing, receiving a blood transfusion , 
family contact with HCV infected person and having inject drug use were observed at risk 
factors with anti-HCV (40).   
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Similar study conducted in Addis Ababa, Ethiopia among HIV positive and HIV negative 
inhabitants reported that the prevalence of HCV infection was higher among HIV positives 4.5% 
compared with HIV negative patients 0.8% (30). Another study conducted felgehiwot referral 
hospital showed that the prevalence of HBsAg and anti-HCV antibody were 2.0% and 5.5%, 
respectively among HIV positive children (41). In 2012, a cross sectional study conducted in 
Debretabor hospital showed that the prevalence of HBsAg was 6.1% and that of anti-HCV  
antibody was 1.3% among a total of 395 HIV infected individuals (42). In Gondar, the 
prevalence of HBV and HCV showed that 5.6% and 5.0% respectively but only 1.1% were co-
infected with both HBV and HCV among HIV positive individuals (31).  
Both HBV and HCV are transfusion transmissible infections (TTIs) and because of that many of 
the blood banks all over the world screen blood donors for HBV, HCV, HIV and other TTIs. The 
magnitude of HBV and HCV among apparently healthy blood donors varies from country to 
country. Recently, Baha et al reported a prevalence of 1.8% and 1.58% for HBV and HCV 
respectively in the general population and 0.96% HBV with 0.62% HCV prevalence among 
blood donors in Morocco. In this study dental procedure history ,history of jaundice and history 
of sexual behaviors were observed at major risk factors of HBsAg and surgical history were 
observed anti-HCV among the general population  (43). In Jordan, the prevalence of HBV and 
HCV infection among blood donors was reported 1.4% and 0.8% respectively. In this study the 
age was strongly associated with HBV and HCV infection (44). Another study conducted in west 
Bengal, eastern India by the year 2005 reported prevalence 1660 per 100,000 for HBV and 350 
per 100,000 for HCV (45). In the same country, study conducted in Ganesh Shankar Vidyarthi 
Memorial (GSVM) Medical College, Kanpur, India, 20,000 healthy blood donors who were 
HBsAg status using ELISA kit show that the prevalence was 2.25% from March 2002 to June 
2006 (46). On the other hand, Khan et al documented a relatively higher prevalence of HCV 
infection 3.13% among voluntary blood donors in Pakistan (47).  In the same country, Pakistan, 
another study conducted  from years 2005 to 2008 reported prevalence 2.07% HBV and 0.89 
HCV among 3915 blood donors (48). A community based cross sectional study conducted in 
Egypt on 1000 apparently healthy blood donors revealed a 5% prevalence of HBV infection. The 
dental extraction and tattoo were observed at risk factors HBsAg (49).  
 There are also reports that showed the prevalence of both HBV and HCV among blood donors 
recruited for blood donation in different blood banks of Ethiopia. A study done in Amhara and 
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Tigray regional state showed that the of prevalence of HBV and HCV was 6.2% and 1.7% 
respectively among blood donors (28). 
In Gondar, a study showed that a 6% and 1% prevalence of HBV and HCV respectively among 
medical waste handlers and non clinical waste handler prevalence of 1% HBV and 0% HCV  (2).  
The prevalence of HBV and HCV infection was reported 4.7% and 0.7% respectively among 
apparently healthy blood donors in University of Gondar hospital (29). In the same country 
another study conducted among street dweller reported for the prevalence of HBsAg was 10.9%. 
Sero positivity HBV infection was higher in females 28.9% than in males 8.3%. In this study 
showed that age of street dweller were found to be a significantly associated HBV infection (50). 
The prevalence of HBV and HCV infection among military groups was investigated in different 
countries previously. For instance, In India armed forces reported  a 7.9% overall prevalence of 
HBV infection and sero-prevalence of HBV infection was significantly associated with history of 
sexual intercourse with commercial sex workers (51). A cross sectional study conducted in 
Afghan National Army recruits at the Kabul Military Training Center prevalence of anti- HCV 
showed that 0.82% between February 2010 and January 2011(52). In a hospital based study 
conducted in Pakistan among military personal 47% of the patients were infected with chronic 
HCV infection (53). Another study conducted in the same country, Pakistan, in two military 
hospitals showed a 2.9% and 1.7% prevalence of HBV and HCV infection respectively (54). A 
cross-sectional study conducted in Senegal, the overall prevalence of HBsAg was 10.8% among 
1224 Senegal military (55). A study was done military recruits in Greece the overall prevalence 
of HBsAg showed that 0.32% among 1,840 participants from 2004 -2005 (56). A study 
conducted in Turkey showed that 2.8% overall prevalence HBV infection among new recruits in 
a military unit and sero prevalence HBV infection was significantly associated having a history 
of living with a hepatitis B carrier and presence of a hepatitis B carrier in the neighborhood or at 
work (57) . 
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3. Significance of the study 
The risk of acquiring both HBV and HCV among military personnel is reported higher in 
different countries.  Living in military camps in particular and other congregate settings in 
general contribute for being at a greater risk for HBV and HCV infection. Peoples suffering from 
repeated injury and admitted to hospitals could be also at higher risk to be infected by these 
viruses. Certain aspects of military services such as an exposure to blood during combat, sexual 
contacts and tattoos increase the risk of HBV and HCV infection. Both HBV and HCV can be 
transmitted through unprotected sexual intercourse and military peoples living in military 
campus are at higher risk to meet commercial sex workers and acquire HBV and HCV. Another 
risk factor could be the displacement of military personnel from place to place. Military’s by 
nature travel from place to place for different reasons and meet different members of the 
migration society. This will force the soldieries to meet another sex partner probably commercial 
sex worker and will be exposed for sexually transmitted infections (STIs) in general and 
infection by HBV and HCV in particular.  
However, both HBV and HCV risk factors and the magnitude of the problem are not well studied 
in Ethiopia among military personnel and also no reports was done in Amhara national state 
particularly in Bahir Dar armed forces of general Hospital. Thus, the aim of this study is to 
determine the prevalence and associated factors of HBV and HCV infection among military 
personnel. Understanding the magnitude of these viruses among military personal possibly 
deliver different relevance. First, it can be used to control theses viruses among people living in 
congregate settings such as military camps and secondly the magnitude of these viruses could 
also help in tracing the prevalence of HIV and other STIs which was valuable to design strategies 
to control the transmission among military people and the general population. The study also 
serves as a baseline information and comparative data for similar future studies. 
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4. Objective 
4.1.  General objective 
          The overall aim of this study was to determine the prevalence of hepatitis B and hepatitis 
C viruses infection and associated risk factors among military personnel attended at Bahir 
Dar armed forces general hospital. 
4.2.   Specific objectives 
1. To determine the prevalence of hepatitis B virus infection among military personnel.  
2. To determine the prevalence of hepatitis C virus infection among military personnel.   
3. To identify the risk factors that contributes HBV and HCV infection among military 
personnel.  
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5.   Materials and method 
5.1. Study area   
The study was conducted at Bahir Dar armed forces general hospital found in Bahir Dar town. 
The town is located in the North West part of Ethiopia and it is the capital city of the Amhara 
national state. The city is located approximately 578 km (360 miles) to the North-west of Addis 
Ababa, and has an elevation of 1,840 meters (6,036 foot) above sea level. According to the 
statistical agency of the town,  Bahir Dar Special Zone has a total population of 221,991, of 
whom 108,456 are men and 113,535 women; 180,174 or 81.16% are urban inhabitants, the rest 
of population are living at rural kebeles around Bahir Dar.  
Bahir Dar armed forces general hospital is found in the Ethiopian ministry of national defense of 
western commend. It is far from approximately 10 kilo meters in the town. Bahir Dar armed 
forces general hospital is currently provides health service to more than 9,000 military and 
military families per year in the surrounding area of the town and adjacent regions. It has 9 
departments with 200 beds for inpatient service at 5 wards: medical, surgical, Special, ICU 
(intensive care unit) and gynecology /obstetrics. The hospital also provides outpatient services 
including emergency and normal OPD.   
 5.2. Study design and period 
Institution based cross sectional study was conducted at Bahir Dar armed forces general hospital 
from the 1
st
 of February 2015 to the 15
th
 of May 2015. 
5.3. Source population 
 The source population was all military patients attending Bahir Dar armed forces general 
hospital. 
      5.4. Study population 
The study population was military patients seeking health service at the outpatient department 
(OPD) of the hospital during the study period.  
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  5.5. Inclusion criteria  
Military personnel seeking health service at the OPD of Bahir Dar armed forces of general 
hospital and can give informed consent and enough amount of blood was included in the study.  
      5.6. Exclusion criteria 
Military personnel who have previously known positive HBV and HCV viruses were excluded 
from the study.   
5.7. Variables  
5.7.1. Dependent variables 
Prevalence HBV and HCV  
               5.7.2. Independent variables 
Age, sex, marital status, work experience, history of hospitalization, history of having received 
blood transfusion, history of surgical procedure, ear/nose piercing, dental extraction, tattooing, 
history of multiple sexual partner, Family history of liver disease, Sharing of shaving blade or 
nail cutter with others, history of jaundice or liver disease, history of sexual transmitted disease 
and ever had war related injury. 
5.8. Sample size and sampling technique        
5.8.1. Sample size determination 
Due to lack of previous studies showing the prevalence of HBV and HCV among Military 
personnel neither in Bahir Dar nor in any parts of the nation Ethiopia, sample size was 
determined for this particular study using a 50% prevalence of both HBV and HCV infection.  
The sample size was determined using single population proportion formula as follows: 
 ni = z
2
α/2 p (1-p)/ d
2
 ; Where   ni= Initial sample size; Z=95% confidence interval; α = the level 
of significance which can be obtained as 1- confidence level; d= Margin of error between the 
sample and the population (d=5%), and P (prevalence) = 50%.  
Accordingly, ni= (1.96)
2
x 0.5(1-0.5) = 384 
(0. 05)2 
Considering a 5% non response rate the final sample size was computed as 403. 
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5.8.2. Sampling technique  
Systematic random sampling technique was used. The number of study participants included was 
out of total military personnel who attended OPD. On average, about 22 military personnel per 
day who sought treatment attended OPD at Bahir Dar armed forces general hospital. Considering 
three months of period, 1320 military personnel were expected to attend the OPD during the 
study period. The number of three month military personnel divided by the number of study 
participant 1320/403= 3, so sampling interval is 3. From the first three participants, one was be 
randomly selected by lottery method, and then every 3
rd
 individuals who attended the OPD was 
selected to participate in the study.   
5.9. Operational defination 
Military:   are forces authorized to use lethal force, and weapons, to support the interests of the 
state and some or all of its citizens.     
5.10. Data collection and process 
5.10.1. Socio demographic data and other risk factors 
Socio demographic characteristics and associated risk factors of HBV and HCV were collected 
using structured and pre test questioner face to face interview by trained health officers. The 
questionnaire was developed in English and then translated in to Amharic (local language) then 
to English. The collected data was checked for its completeness and validity to get a reliable and 
clear data (Annex III). 
5.10.2. Blood specimen collection and processing 
Blood sample was collected by trained laboratory technologist, three milliliters (3ml) of venous 
blood was collected from each study participants. The blood was collected in to sterile plain 
tubes by strictly following standard operational procedures. Then the sample tube was labeled 
with the subject’s code number and the blood specimen was allowed to stand at room 
temperature until completely clotted.  Serum was separated from the clot by centrifugation at 
3000 revelation per minute (rpm) for 5 minutes for checking the presence of HBsAg and anti-
HCV antibody. The sera were then frozen at -20 
0
c until testing. The sera were kept at room 
temperature and screened for HBsAg using commercially available test kit according to the 
manufacturer’s instruction which works based on principle of immunechromatographic assay 
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(One step HBsAg test, Shanghai Eugene Biotech co.,Ltd) which has 96.2% sensitive and a 
specificity of 99.3%  (Annex V).  
Similarly, sera were screened for anti HCV antibody using rapid test kit which works based on 
principle of immunechromatographic assay (Eugene one step hepatitis C virus test, Shanghai 
Eugene Biotech co., Ltd) which has 98.13% sensitivity and 99% specificity (Annex V).      
 5.10.3. Quality control 
Before using the prepared questionnaire for collection of information, it was checked for its 
completeness and validity to get a reliable and clear data. To ensure the quality of the data the 
pre- test was conducted among military attending OPD at 24 
th
 military hospital level two at 
Azezo, Gondar on 5% of sample size. Two days training was given for data collectors on 
procedures, techniques, and ways of expressing the questionnaires to collect the necessary 
information. Every day, the collected data was reviewed and cheeked for completeness by 
principal investigator. For laboratory investigations standardized operating procedures and 
manufacturer’s instructions followed strictly. Known positive and negative samples were run to 
assess the performance of the test kits prior beginning laboratory investigations.  
 5.11. Data analysis and interpretation  
Data was entered and analyzed using statistical package for social sciences (SPSS) version 20 
computer software. Descriptive statistics were used to analyze socio- demographic characteristics, 
prevalence of HBsAg and anti - HCV. The result of the study was summarized using tables, 
graphs and texts. Association between each exposure and sero positivity of HBV and HCV 
infection were determined by using bivariate analysis. Those variables with overall P value less 
than 0.2 in the bivariate analysis were entered in to multivariable model. Odds ratio was used to 
measure the strength of an association. Variables having P-value < 0.05 was considered 
statistically significant.  
5.12. Ethical consideration 
The study was conducted after getting ethical approval from the ethical committee of School of 
Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of 
Gondar, Department of Medical Microbiology. Bahir Dar armed forces general hospital had 
communicated through written paper obtained from College of Medicine and Health Sciences, 
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University of Gondar and permission was obtained from the administrator of the hospital.  The 
study participants were informed about the objectives of the study and written informed consent 
was obtained from each participants. They were also told that they have the right not to 
participate in the study. In addition they were also told that the study did not have any phisical 
harm except the minimal risk associated with blood drawing. Only voluntary participants were 
recruited. They were also informed that all the information and results of their sample was kept 
confidential by using codes instead of any personal identities. The results were notified to study 
participants. Individuals found to be HBV or HCV were linked to OPD physician and nurses for 
further monitoring and management. 
5.13. Dissemination of the result 
The result of the current study will be submitted to University of Gondar, College of Medicine 
and Health Sciences, School of Biomedical and Laboratory science, Department of Medical 
Microbiology, The Amhara National state Health bureau and Bahir Dar Military hospital. The 
result of this research will be also published on reputable journals which will disseminate the 
existing condition concerning undiagnosed hepatitis B and C virus infection among military 
personnel seeking health service at Bhair Dar armed forces general hospital.   
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6. Results  
     6.1. Socio-demographic characteristics  
A total of 403 individuals were enrolled being 362 (89.8%) males with the mean   age of 32.6 ± 7 
years. Two-hundred fifteen (53.4%) clients were married, 178 (44.2%) single and 9 (2.2%) 
divorced. Data on educational status 194 (48.2%) accomplished the college or higher education 
and the other 183 (45.4%) had high school education. Three-hundred nineteen (79%) were 
residents of urban but the other 85 (22%) were living in rural areas. Majority of the study 
participants were orthodox followers in religion 325 (80.6%) (Table1). 
Table 1Socio-demographic characteristics of military personnel at Bahir Dar armed forces 
of general hospital, February – May, 2015(n=403) 
Variable      Frequency 
Number Percent 
Sex Female 41 10.2 
Male 362 89.8 
Age 20-29 160 39.7 
30-39 172 42.7 
40-49 69 17.1 
> 50 2 0.5 
Work experience(year) < 10 179 44.4 
10 – 20 184 45.6 
>20 41 10.1 
Current residence  Urban 319 79.2 
Rural 85 21.9 
Educational status  Elementary 26 6.4 
High school 183 45.4 
College and above 194 48.2 
Religion  Orthodox 325 80.6 
Muslim 42 10.4 
Others 36 9 
Marital status  Single 178 44.2 
Married 215 53.4 
Widowed 1 0.2 
Divorced 9 2.2 
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6.2. History of exposures to different risk factors of HBV and HCV  
History of hospitalization and dental extraction were the most frequently reported exposures 
which account 135 (33.5%) and 116 (28.8%) respectively. Three hundred ninety two (97.3 %) of 
them reported no history of blood transfusion and the remaining 11 (2.7 %) participants had 
received blood transfusion. Concerning the history of surgery; 39 (9.7%) had surgical history and 
the rest i.e. 364 (90.3%) no history of surgical operation. Ninety-one (22.6 %) of the military 
personnel have no sexual partner, 298 (74 %) have one sexual partner and the remaining 14 
(3.4%) have multiple (above two) sexual partners. The assessment data on the history of liver 
disease within the family of the military personnel’s showed that the majority 385 (95.8%) had 
no any family history of liver disease and the rest 17 (4.2 %) had family history of liver disease. 
The result of this study showed that 5 % of the participants had history of sexual transmitted 
infection and 15.4% history of ear piercing (Table 2). 
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Table  2. History of exposures for HBV and HCV among military at Bahir Dar armed 
forces of general hospital, February – May, 2015 (n=403). 
Variable Frequency 
Number Percent 
History of hospitalization 
 
History of body tattooing                            
                              
Yes 135 33.5 
No 
Yes 
No 
268 
69 
334 
66.5 
17.1% 
82.9 
History of dental extraction Yes 116 28.8 
No 287 71.2 
History of received blood transfusion  Yes 11 2.7 
No 392 97.3 
Surgical history  Yes 39 9.7 
No 363 90.3 
Number of sexual partner  No 91 22.6 
One 298 74 
Two and above 14 3.5 
Family history of liver disease  Yes 17 4.2 
No 385 95.8 
History of liver disease  Yes 12 3 
No 391 97 
Sharing of shaving blade or nail cutter  Yes 23 5.7 
No 380 94.3 
Ear piercing  Yes 62 15.4 
No 341 84.6  
Nose piercing  Yes 10 2.5 
No 392 97.5 
Circumcision (for only males) Yes 343 94.8 
No 19 5.2 
History of sexual transmitted infection  Yes 20 5 
No 383 95.1 
War related injury  Yes  62 15.4 
No 341 84.6 
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     6.3. Sero-prevalence of HBV and HCV  
Among the 403 military personnel participated in the current study 4.2% (17/403) was positive 
for HBsAg but only 0.2% (1/403) person was positive for anti-HCV antibody. The overall viral 
hepatitis caused by HBV and HCV was found 4.5% (18/403). In this study the point prevalence 
of HBV infection was 318.2/100,000 and that of HCV 15.2/100,000. However, none of the 
military personnel was infected by both HBV and HCV. 
    6.4. Hepatitis B virus and hepatitis C virus infection in relation socio-  
          demographic characteristics  
The highest prevalence of HBsAg 11.2 % (8/71) was observed among military personals with the 
age of 40 and above followed by the age group between 30 to 39 years of age 3.5% ( 6/172).  
Relatively higher prevalence of HBV infection was observed among Rural dweller 5/84 (6 %). 
Hepatitis B virus prevalence was higher among married personnel’s 12/215 (5.6 %) than single 
military personnel’s 5/178 (2.8%) and military personnel’s who attended for  high school 
education showed a relatively higher prevalence of HBV infection 6% (11/183) than military 
personals attended elementary school or college education. The prevalence of HBV infection 
5.46 % (10/183) was higher among military personnel that served for 10 – 20 years within the 
military group than those that served less than 10 years (Table 3). 
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Table  3. Demographic characteristics of military personnel and prevalence of HBV and 
HCV at Bahir Dar armed force general hospital, February – May, 2015 (n=403) 
Variable  Total (n 
%) 
                 HBV                     HCV 
   Positive 
n (%) 
Negative  
n (%) 
Positive 
n(%) 
Negative 
n (%) 
Sex Female 41(10.2) 2 (4.9) 39 (95.1) 0 41(100) 
 Male 362 (89.8) 15 (4.2) 347 (95.8) 1(0.27) 361 (99.7) 
Age (year) 20 -29 160 (39.7) 3 (1.87) 157 (98.1) 0 160 (100) 
 30 -39 172 (42.7) 6 (3.5) 166 (96.5) 0 172 (100) 
 40+ 71 (17.6) 8 (11.2) 63 (88.7) 1(1.4) 70 (98.5) 
Residence Urban 319 (79.1) 12 (3.8) 307 (96.2) 1(0.3) 318 (99.7) 
 Rural 84 (20.8) 5 (5.9) 79 (94) 0 84 (100) 
Educational 
status 
Elementary  26(6.5) 0 26 (100) 0 26 (100) 
 High 
school 
183 (45.4) 11(6) 172 (93.9) 1(0.54) 182 (99.4) 
 Collage 
and above 
194 (48.1) 6 (3.09) 188 (96.9) 0 194 (100) 
Religion  Orthodox 325 (80.6) 14 (4.3) 311(95.6) 1(0.3) 324 (99.6) 
 Muslim 42 (10.4) 2 (4.7) 40 (95.2) 0 42 (100) 
 Others 36 (8.9) 1(2.7) 35 (97.2) 0 36 (100) 
marital status  Single 178 (44.2) 5(2.8) 173 (97.1) 0 178 (100) 
 Married 215(53.34)   12(5.6) 203 (50.3) 1 (0.46) 214 (99.5) 
 Widowed 2 (0.49) 0 2 (100) 0 2 (100) 
 Divorced 8 (1.98) 0 8 (100) 0 8 (100) 
work 
experience(year) 
<10 179 (44.4) 5(2.79) 174 (97.2) 0 179 (100) 
 10 -20 183 (45.4) 10 (5.46) 173 (94.5) 1(0.5) 182 (99.4) 
 >20 41(10.1) 2 (4.87) 39 (95.1) 0 41 (100) 
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6.5. Association between risk factors for viral hepatitis (HBV and HCV) infection   
       among military personnel at Bahir Dar armed general hospital  
In bivariate logistic regression analysis risk factors such as history of hospitalization, tattooing, 
dental extraction, family history of liver disease, ear piercing, war related injury, history of blood 
transfusion, number of sexual partners, history of jaundice and sharing of shaving blade or nail 
cutter were not significantly associated with infection caused by the hepatitis viruses. However, 
demographic variable such as age (p= 0.003; COR 7.59; 95% CI 1.991, 28.992) and risk factors 
such as nose piercing (COA 5.85; 95% CI 1.153, 29.93, p=0.033) and sexual transmitted 
infections COR 4.33; 95% CI 1.143, 16.39, p=0.031) were significantly associated with infection 
caused by the hepatitis viruses.  
For the multivariate regression analysis, all covariates that had P-value of ≤ 0.2 and variables 
that had significant association with the hepatitis viruses’ infection during the bivariate analysis 
were attempted. The backward stepwise regression which controls the problem of confounding 
was employed and only STI contributing factor remained to be significantly associated with viral 
hepatitis (HBV and /or HCV) infection (P ≤ 0.05). Moreover, military personals that had history 
of STIs were found 5 times at a higher risk to be infected by hepatitis viruses (HBV / or HCV) 
than compared with military personnel that had no history of STIs (P value =0.019; AOR 5.126; 
CI 95% 1.306, 20.126) (Table -4).  
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Table  4. Bivariate and multivariate analysis of risk factors association with hepatitis virus 
infection. 
Variable                                                    
 
Viral hepatitis  COR (95% CI) P-
Value            
AOR (95% CI) P-
Value Positive 
N(%) 
Negative 
N(%) 
Sex 
  
Female 2 39 1:00     
Male 16 346 0.902 (0.200,4.069) 0.89   
Age 20-29 3 157 1:00     
30-39 6 166 1.89 (0.465,7.694)     
40+ 9 63 7.59 (1.991,28.992) 0.003   
Current 
residence 
Urban 13 306 1:00     
Rural 5 79 1.490 (0.516,4.303) 0.461   
Educational 
status  
Up to 12 12 197 1:00     
College 
& above 
6 188 0.524 (0.193,1.424) 0.205   
Religion  Orthodox 15 310 1:00     
Muslim+ 
others 
3 75 .827(0.233,2.929) 0.768   
Marital 
status  
 
Single 5 173 1:00     
Married 13 202 2.355 (0.824,6.735) 0.11   
Work 
experience  
<10 5 173 1:00    
10-20 11 173 2.20 (0.749, 6.46) 0.152   
>20 2 39 1.77 (0.332, 9.485) 0.503   
Hospitalizat
ion 
No 11 257 1:00     
Yes 7 128 1.278 (0.484,3.374) 0.621   
Tattooing  No 13 321 1:00     
Yes 5 64 1.929 (0.665,5.600)  0.227   
Dental 
extraction  
No 11 276 1:00     
Yes 7 109 1.611(0.609,4.264) 0.337   
Surgical 
history 
No 14 350 1:00     
Yes 4 35 2.857(0.892,9.153) 0.077   
Number of 
sexual 
partner 
0 2 89 1    
1 14 284 2.19(0.489, 9.837) 0 .305    
≥2 2 12 7.41(0 .954, 57.64) 0 .055     
Family 
history of 
liver 
disease  
No 16 369 1:00     
Yes 2 16 2.88(0.610,13.621) 0.181   
Ear 
piercing  
No 15 326 1:00     
 
Yes 3 59 0.905(.254,3.223) 0.877   
Nose 
piercing  
No 16 376 1:00     
Yes 2 8 5.85 (1.153, 29.93) 0.033   
STI   No 15 368 1:00                1  
Yes 3 17 4.33 (1.143,16.39) 0.031 5.126(1.306,20.126) 0.019 
War related 
injury 
 
No 15 326 1:00     
Yes 3 59 0.905 (.254,3.223) 0.877   
COR – Crude odds ratio,   CI – Confidence interval, STI – Sexual transmitted infection, AOR –Adjusted 
odds ratio, 0 = no sexual partner, 1= one sexual partner,   ≥ 2= sexual partner two and above  
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7. Discussion 
Both hepatitis B and C are common infections affecting masses and are the leading causes of 
chronic liver disease. Hepatitis is an inflammation of the liver, most commonly caused by a 
viral infection. Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections account for a 
substantial proportion of liver diseases worldwide. These viruses are responsible for liver 
damages ranging from minor disorders to liver cirrhosis and hepatocellular carcinoma (HCC). 
However, data regarding HBV and HCV viruses’ prevalence among military personnel in the 
Amhara National state is lacking. 
The result of the present study showed that the prevalence of hepatitis B virus infection was 
4.2%. A recent study in Gondar, Ethiopia showed a prevalence of 1 % for HBV infection in 
the non clinical waste handler without any risk for infection (2). This prevalence difference 
between the military groups and other members of the population in the same administrative 
region may demonstrate that the military groups are at relatively higher risk for hepatitis B 
virus infection. The prevalence of HBV infection (4.2%) among Military groups found in 
Bahir Dar armed forces general Hospital was nearly similar to the prevalence of HBV 
prevalence reported from apparently healthy blood donors in Gondar (4.7%) (29) . However, 
the prevalence of HBV found in the current study was lower than the prevalence reported 
from Gondar town street dwellers (10.9%) (50). Previously, Higher prevalence of HBV 
infection (10.4%) was also reported in Woldia from prisoners (36). Another Higher 
prevalence of HBV infection was also reported in some African countries among different 
population groups. For example, a prevalence of  8.2% was reported in Sudan among healthy 
people (35), 23% in Nigeria among prisoners (34) and  11.9% among HIV positive patients in 
Nigeria (37).  
The prevalence of HBV infection among military groups was also reported higher in some 
African and Asian countries. In India and Senegal the prevalence of HBV infection among 
military groups was reported 7.9%  and 10.8%  respectively (51, 55). The discrepancy might 
be due to the differences in diagnostic methods. In-contrast, the prevalence HBV infection in 
this study is relatively higher than a previous study done in Pakistan 2.9 % (54), in Greece 
0.32% (56) and in Turkey 2.8 % (57)  among military groups. 
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The prevalence of HBV and HCV infection found in the current study can be graded 
intermediate and low according to WHO criteria (10) .The prevalence of HBV infection can 
be graded high when the prevalence is > 8%, intermediate when the prevalence is between 2-
8% and low when < 2% (58). Hepatitis C virus infection can be also graded high, moderate or 
low when the prevalence is >3.5%, 1.5%-3.5% and <1.5% respectively (59) . 
In the current study, the prevalence of HCV infection was found 0.2%. This prevalence is 
nearly similar to previous reports among medical waste handler 1% and prevalence reported 
among blood donors (0.7%) in Gondar (2, 29) . More over this finding is in agreement with 
the prevalence of HCV infection was reported 0.8% in Nigeria among apparently health 
people, 0.62% in Morocco, 0.8% in Jordan, 0.89% in Pakistan among blood donors (38, 43, 
44, 48). The present study also similar with 0.82 % prevalence of HCV among military 
groups in Kabul military Training Center (52).  
On the other hand, relatively higher prevalence of HCV infection 1.7% was reported in Pakistan 
among military groups (54). The difference might be due to the presence of high risk groups 
such as intravenous drug users as well as difference including the use of more reliable diagnostic 
methods to detect HCV infection in those countries. 
The proportion of HBV infection was higher among military personals with the age of 40 and 
above 11.2% (8/71) followed by the age group between 30 to 39 years of age 3.5% (6/172). 
In a study conducted in China investigated the clinical and virological characteristics of HBV 
in chronic HBV infected patients of different ages and reported significantly different HBV 
clinical and virological characteristics in patients with chronic HBV infection of different 
ages. Among patients below 20 years of age immune tolerance accounted for 86.05% and 
among patients in the above 40 age group, there were markedly more reactivation cases than 
in any other group (60). Moreover, it was also observed that by the age of 40 years, 87% of 
the Nigerian population has at least one HBV serologic marker (61).  
In the current study relatively higher prevalence of HBV infection was observed among rural 
dweller 6 % (5/84). This may suggest that horizontal transmission aided by cultural or 
behavioral factors and clustering of carriers could be the main determinant of HBV 
prevalence in among the rural dweller military groups investigated military at Bahir Dar 
armed forces of general hospital. The prevalence of HBV was higher among married military 
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personnel’s (5.6 %) than single military (2.8%). One possible reason for this could be 
displacement of military from the residence where their family was living as military are 
movable and standby which may force them for multiple sexual practices.  However, there 
are reports that showed marital status did not affect the carriage of HBsAg (55) .  
However, multivariate linear regression analysis of risk factors such as history of 
hospitalization, tattooing, dental extraction, ear piercing, war related injury, and sharing of 
shaving blade or nail cutter were not significantly associated with infection caused by the 
hepatitis viruses. Contrary to these findings, a study conducted in Bahir Dar showed that 
significant association between history of blood transfusion, body tattooing, previous history 
of surgery and unsafe injection to HBV infections among pregnant women (62). A similar 
study, which was conducted in Egypt identified these variable as significant risk factors for 
HBV infection (63). Study participants who have body tattooing on any part of their body 
was also 5.7 times more likely to be HBsAg positive. Studies conducted from Bamako, Mali 
identified that body tattooing has a significant association with HBV infection (64). 
Risk factors such as previous exposure to STI showed significant association with hepatitis B 
virus infection. There are some evidences demonstrate that military groups are at a higher 
risk of acquiring hepatitis causing viruses compared with that of the general population. For 
that matter, soldiers are considered as a gateway group for sexually transmitted diseases 
(STIs) (55). 
Although only one soldier was positive for HCV infection in the present study, this client was 
negative for HBV.  Several reports indicated that co-infection with both HBV and HCV is 
uncommon. In a study conducted among blood donors in the Amhara and Tigray national 
state there was no HBV and HCV co-infection found (28). By another study report from 
Nigeria among prisoners only 0.07% were co-infected with both HBV and HCV (34). 
Therefore, HCV infection is uncommon among HBV positive patients and some authors 
describe mutual inhibition (65) . 
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8. Limitation of the study 
 Due to the limited resources, only rapid test kits were used for detection of HBsAg and 
anti- HCV antibody. Confirmatory tests like ELISA were not possible to use in this study  
 Since this study was hospital based study, it may not reflect the actual prevalence among 
the general military in the area. 
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  9. Conclusion and recommendation 
          9.1. Conclusion  
The prevalence of HBV and HCV infections among military personnel at Bahir Dar armed forces 
general hospital can be graded as intermediate and low respectively. Moreover, there was 
statistically significant association between previous history of STIs and to that of the HBV 
infection.  
        9. 2.   Recommendations 
The intermediate prevalence of HBV infection among military groups dictates to formulate 
appropriate preventive method. Screening for HBV infection among known sexual partners 
could be one possible strategy for regular check up. Vaccination against HBV might be required 
to control the transmission of HBV from the military group to the community. Further studies 
needs to be carried out in the area with relatively improved study designs and diagnostic methods 
to know the true burden of HBV and HCV infections in military personnel. 
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11. Annexes 
Annex I. English version information sheet and consent form 
        Information sheet  
Study title: The sero - prevalence of HBV and HCV infection and associated risk factors among 
military personnel at Bahir Dar armed forces general hospital, Northwest Ethiopia. 
Name of investigator: Tigist Birku 
Name the organization: University of Gondar College of Medicine and health sciences school 
of biomedical and Laboratory sciences. 
Name of the sponsor: Amhara Regional State Health Bureau. 
Purpose of the study: HBV and HCV infections are major health problems. So that I am to 
conducts a study with objective of investigate prevalence of HBV and HCV infection in military 
patients attending military service hospital. The knowledge gained from this study is believed to 
help the management and control of these viruses.  
Participation 
 I am asking to voluntarily participate in this study. What is expected from everyone is to be 
examined for HBV and HCV and be asked to answer few questions in relation to risk factors. 
The laboratory examination involves collection of 5 ml venous blood. All samples are collected 
using sterile and disposable equipments: tubes, syringes and needles. 
Risk and discomfort associated 
By participating in this study you may feel that it has some risk or discomfort by taking 5ml of 
blood but doesn’t have any harm to your health except minor needle brick injury pain which lasts 
only for micro second. 
Benefits 
 If there is any positive finding in laboratory investigation the result will be communicated to 
your physician and prescription of treatment and advice will be effected. 
Confidentiality 
Any information that is obtained in connection with this study and that can be identified with you 
will remain confidential. The information collected about you will be coded using numbers. 
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Sharing the result 
At the end of this study we write a report about the results of the study through publication or 
any other means. The reports won’t bear any information relevant to your personality e.g. your 
name or identity. We assure you the confidentiality of such information. Thus we also need your 
permission to use the test results for writing a report. 
Participation and withdrawal  
You can choose whether to be part of the study or not. You may withdraw at any time without 
consequences of any kind. You may also refuse to give any sample and/or information. 
Contact Address 
If you have any further question and in case of urgency you can contact the principal investigator 
at any time using the following address:- 
Name:- Tigist birku (Principal investigator) 
Address: - University of Gondar College of Medicine and Health Sciences 
School of Biomedical and Laboratory Science 
City: - Gondar 
Mobile No. : 251918414446 
Email:- tigib41@gmail.com 
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Consent form 
I, the undersigned individual have been well informed about the objectives of the study as 
described below. 
Dear respondent my name is Tigist birku .The aim of the study is to assesses hepatitis B and 
hepatitis C virus infection and risk factors among military. Your response helps us to find out 
risk factors associated with hepatitis B and C virus infection so that the possible solution will be 
given by the responsible bodies. For the research we need your response for questions and blood 
sample to detect HBV and HCV. For any question you can ask the principal investigator .you 
have the right to not to participate or withdraw. All the information you will give us will be used 
for research purposes and kept confidential.  
Name ………………………………. 
Signature……………………………    
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ANNEX II. Amharic Version Study Participant Information and Consent Form 
ለጥናቱ  መረጃ ና ተሳታፊነት መግለጫ ቅጽ 
የ ጥናቱ  መረጃ  
የ ጥናቱ ርዕስ  
የ ሂፓታይትስ ቢ እና ሲ ቫይረስ በባህርዳር በሚገ ኝው በወታደሮች ሆስፒታሌ ውስጥ በሚታከም ወታደሮች  
ሊይ ያሇውን ስርጭትና አጋሊጭ መንስኤዎችን ማወቅ ፡ ፡  
የ አጥኝው ስም: ትዕግስት ብርቁ  
የ ሚያስጠናው ድርጅት ስም ፡ - ጎ ንደር ዩኒ ቨርሲቲ ህክምናና ጤና ሳይንስ ኮላጅ ባዩሜዲካሌና ሊብራቶሪ 
ሳይንስ ትምህርት ክፍሌ 
 የ ጥናቱን ወጭ የ ሚሸፍነ ውን ድርጅት ስም :- የ አማራ ክሌሌ ጤና ቢሮ  
የ ጥናቱ አሊማ ፡ - የ ሄፓታትስ B እና ሲ ቫይረሶች በህሙማን በወታደሮች ያሇውን ስርጭት ሇማጥናት 
የ ታቀደ ነ ው ፡ ፡  
በጥናቱ ስሇመሳተፍ 
በዚህ ጥናት መሳተፍ በሙለ ፈቃደኝነ ት ሊይ የ ተመሰረተ ነ ዉ፡ ፡  ስሇሆነ ም በጥናቱ እንዲሳተፉ 
ፈቃደኛነ ትዎን እንጠይቃሇን ፡ ፡  ሇመሳተፍ ከፈቀዱ 3 ሚሉ ሉትር የ ደም ናሙና ከክንድዎ ተወስዶ 
የ ሊቦራቶሪ ምርመራ ይደረግልታሌ ፡ ፡  የ ሊቦራቶሪ ምርመራውም ሄፓታይተስ “ቢ” እና “ሲ” ቫይረስን በደሞ 
ዉስጥ መኖር ና አሇመኖር ማረጋገ ጥ ይሆናሌ ፡ ፡  የ ደም ናሙናዉም የ ሚወሰደዉ ንጽህናዉ በተጠበቀ አዲስ 
እና በታሸገ  መርፌ ና ስሪንጅ ’ዉ፡ ፡  
በጥናቱ ሉከሰቱ የ ሚችለ ተያያዥ ችግሮች 
3 ሚሉ ሉትር የ ደም ናሙናዉን ሇመዉሰድ መርፌ ሲገ ባ ከሚፈጥረዉ የ ቅጽበት የ ህመም ስሜት በስተቀር የ ጎ ሊ 
ችግር አያመጣም ነ ገ ር ግን ምቾት ካሌተሰማዎት ሀኪም እንዲያይዎት ይደረጋሌ ፡ ፡  
በጥናቱ በመሳተፍ የ ሚገ ኝ ጥቅም 
የ ደም ናሙና የ ሊብራቶሪ ዉጤት ምንም አይነ ት ችግር ካሳየ  የ መድሃኒት ትእዛዝ ና የ ባሇሙያ ምክር 
ይሰጥዎታሌ፡ ፡  
 
 
የ ጥናቱ መረጃዎች ሚስጥራዊነ ት 
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በጥናቱ ውስጥ የ ተሰበሰቡ ማናቸዉም ግሊዊ መረጃዎች ሚስጥራዊነ ታቸዉ የ ተጠበቀ ይሆናሌ፡ ፡  ከማንነ ትዎ ጋር 
በቀጥታ ተያያዥነ ት ያሊቸዉ መረጃዎች በሙለ በዋና ተመራማሪዉ ሚስጥራዊ በሆነ  የ መረጃ ጥንቅር ዘዴ 
ከተቀየ ሩ በኃሊ ብቻ ሇምርምር ሂደቱ የ ሚዉለ ይሆናለ፡ ፡  
የ  ጥ ና ቱ ን ዉጤት ስ ሇ ማሳ ወ ቅ 
ከዚህ ጥናት ውጤት በተሇያዩ የ ህትመት ውጤቶች የ ሚቀርብ ሲሆን ይህ ከማንነ ቶዎ ጋር የ ተያያዘ ምንም 
አይነ ት መረጃን አያካትትም ፡ ፡  ስሇዚህም የ ጥናቱን ውጤት በሪፖርት እናቀርበው ዘንድ ፈቃደዎን 
እንጠይቃሇን ፡ ፡  
ከጥናቱ ስሇ መዉጣት ና ስሇማቋረጥ 
ይህ ጥናት በፈቀደኝነ ት ሊይ የ ተመሰረተ እንደመሆኑ መጠን በማንኛዉም ወቅት በፈቃድዎ ከጥናቱ መዉጣት 
ይችሊለ፡ ፡  ከጥናቱ ቢወጡም እንኳን የ ተሇመደዉን የ ህክምና እርዳታ በጤና ተቋሙ ዉስጥ በማንኛዉም ጊዜ 
የ ማግኘት መብት አሌዎት፡ ፡  
ከጥናቱ ጋር በተያያዘ ማናቸውም ጥያቄ ቢኖርዎ በሚከተሇዉ አድራሻ ጥያቄዎን ማቅረብ ይችሊለ፡  - 
ዋና ተመራማሪ፡  -ትዕግስት ብርቁ   
አድራሻ፡  - ጎ ንደር ዩኒ ቨርስቲ  
ስሌክ፡  - 251918414446 (ሞባይሌ) 
ኢሜሌ ፡  - tigib41@gmail.com 
 
 
 
 
 
 
 
 
 
 
 
 
 
ስሇ ስምምነ ቱ ማረጋገ ጫ ፊርማ 
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እኔ ስሜ ከታች የ ተገ ሇፀዉ የ ጥናቱ ተሳታፊ ሇመሆን ስወስን የ ጥናቱን አሊማዎች አሰራሮችና ቅድመ 
ሁኔታዎች በግሌጽ በመረዳትና ከጥናቱ ተሳታፊነ ት ፈቃደኛነ ቴን በማንኛዉም ደረጃ የ ማንሳት መብቴን 
በማረጋጥ ነ ዉ፡ ፡  
እኔ ------------------------------------- በጥናቱ ተሳታፊ መሆኔ ን በፊርማዬ 
እያረጋገ ጥሁ ይህንን ስወስን በጥናቱ ሳቢያ ሉከሰቱ የ ሚችለ አደጋዎች በሚገ ባ የ ተረዳሁ ና ከጥናቱ 
በማንኛዉም ደረጃ እራሴን ሇመሰረዝ ብወስን ተገ ቢ የ ሆኑ ህክምናዎች ና እገ ዛዎች ሁለ እነ ደማይነ ፍጉኝ 
በማመን ነ ዉ፡ ፡  እነ ዚህ መረጃዎች ሁለ በሚገ ባ በምረዳዉ ቋንቋ የ ተገ ሇጸሌኝ መሆኑን በፊርማዬ 
አረጋግጣሇሁ ፡ ፡  
የ ጥናቱ ተሣታፊ  ሙለ ስም፡  ---------------------------------------------- 
             ፊ ር ማ፡  --------------------- 
የ ተመራማሪዉ ሙለ ስም፤  ------------------------------------------------- 
               ፊርማ፡  ---------------------- 
የ ምስክር ሙለ ስም፡  ---------------------------------------------------
-------  
               ፊርማ፡  ------------------------ 
 
 
 
 
 
 
 
 
 
 
 
  
ANNEX III.    English Version of Questionnaire 
                             University of Gondar 
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                        College of Medicine and Health Sciences 
                    School of Biomedical and Laboratory Science 
Part 1 Questioners to assess socio demographic characteristics 
Code………                                                          Date 
Ser.No. Questions Categories and Code skip 
1.1 Sex 1. Female 
2. Male 
 
1.2 How old are you? ……..age(yr)  
1.3 Work experience ……………yr  
1.4 Current residence? 1. Urban 
2. Rural 
 
1.5 Educational status 1. Elementary 
2. High school 
3. Collage and above 
 
1.6 Religion 1. Orthodox 
2. Muslim 
3. Others 
 
1.7 Marital status 1. Single 
2. Married 
3. Widowed 
4. Divorced 
 
 
 
 
 
 
 
 
 
Part 2 RISK ASSESMENT 
Ser. No. Question Categories and Code Skip 
2.1 History of hospitalization? 0.Yes  
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1. No 
2.2 History of body Tattooing? 0. Yes 
1. NO 
 
2.3 Dental extraction at home or 
health facility? 
0. Yes 
1. No 
 
2.4 History of blood transfusion 
history? 
0. Yes 
1. No 
 
2.5 History of surgical history 0. Yes 
1. No 
 
2.6 How many  sexual partners do 
you have 
0.  No       
1. One 
2.  two and above 
       
 
 2.7 Family history of liver 
disease? 
0. Yes 
1. No    
 
2.8         History of jaundice or liver 
disease? 
0. Yes 
1. No 
 
2.9 Sharing of shaving blade or 
nail cutter with others? 
0. Yes 
1. No 
 
2.10 Ear piercing? 0. Yes 
1. No 
 
2.11 Nose piercing? 0. Yes 
1. No 
 
2.12 Circumcision? 0. Yes 
1. No 
 
2.13 History of sexual transmitted 
infection? 
0. Yes 
1. No 
 
2.14 Ever had war related injury? 0. Yes 
1. No 
 
ANNEX IV. Amharic Version of Questionnaire 
ክፍሌ1  ማህበራዊ ነ ክ መረጃዎች 
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ኮድ : _____________                  ቀን: _____________ 
ተራቁጥር ጥያቄ አማራጭ መሌሶች  
 
ወደ ጥያቄ 
…… ይሇፉ  
1.1 ፆ ታ 1. ሴ ት 
2. ወ ን ድ 
 
1.2 እድሜ [ ______] አመት  
1.3 ወታደር ሁነ ው  ስንት አመት 
ሰሩ?  
(……………………..) አመት  
1.4 የ መኖሪያ አካባቢ? 1. ከተማ  
2. ገ ጠር 
 
1.5 የ ትምህርት ደረጃ 1. የ መጀመሪያ ደረጃ ት/ት (1–8) 
2. የ ሁሇተኛ ደረጃ ት/ትና መሰናዶ(9-12) 
3. ኮላጅ  እና ከዛ በሊይ  
 
1.6 ሀይማኖት 1. ኦርቶዶክስ 
2. ሙስሉም 
3. ላሊ፡  ይጠቀስ   
 
1.7 የ ጋብቻ ሁኔታ  1. ያሊገ ባ/ች 
2. ያገ ባ/ች 
3. የ ሞተበት/ባት   
4. የ ፈታ/ች  
 
 
 
 
 
 
 
 
ክፍሌ 2፡  ሇሄፓታይትስ ቢ ና ሲ አጋሊጭ የ ሆኑ ሁኔታዎችን የ ሚዳስሱ ጥያቄዎች 
ተራቁጥር. ጥያቄ አማራጭ መሌሶች  
 
ወደ ጥያቄ …… 
ይሇፉ  
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2.1 ከዚህ በፊት ተኝተው ታክመው 
ያውቃለ? 
0. አዎ 
1. አሊውቅም 
 
2.2 ሰዉነ ትዎን ተነ ቅሰዉ ያዉቃለ? 2. አዎ 
3. አሊውቅም 
 
2.3 ጥርስውን አስነ ቅሇዉ ያዉቃለ? 0.  አዎ 
4. አሊውቅም 
 
2.4 ደም ከላሊ ሠዉ ተሰጥቶዎት 
ያዉቃሌ? 
0. አዎ 
1. አሊውቅም 
 
2.5 ማንኛዉንም አይነ ት ቀዶ ጥገ ና 
አሰርተዉ ያዉቃለ? 
0. አዎ 
1. አይደሇም 
 
2.6 ከአንድ በሊይ የ ፍቅር ጉደኛ 
ነ በረዎት? (ከአንድ ሠዉ በሊይ 
የ ግብረስጋ ግንኙነ ት ነ በረዎት?) 
0. የ ሇኝም  
1.  አንድ  
2. ሁሇት 
 
2.7 ከቤተሰቦዎ በጉበት ህመም የ ተጠቃ 
አሇን?  
0. አዎ 
1. የ ሇም 
 
2.8         በጉበት በሽታ ተጠቅተው ያውቃለ?  0. አዎ 
1. አሊውቅም 
 
2.9 ላሊ ሰዉ በተጠቀመበት ምሊጭ 
ወይም የ ጥፍር መቁረጫ ተጠቅመዉ 
ያዉቃለ? 
0. አዎ 
0. አሊውቅም 
 
2.10 ጆሮዎን ተበስተዉ ያዉቃለ? 0. አዎ 
1. አሊውቅም 
 
2.11 አፍንጫዎን ተበስተዉ ያዉቃለ? 0. አዎ 
1. አሊውቅም 
 
2.12 ግርዛት ተገ ርዘዋሌ? 0. አዎ 
1. አሊውቅም 
 
2.13 የ አባሊዘር በሽታ ታመው ያውቃለ? 0. አዎ 
1. አሊውቅም 
 
2.14 በጦርነ ት ወቅት ቆስሇው  
ያውቃለ? 
0. አዎ 
1. አሊውቅም 
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Annex V. Laboratory Procedures and Data Collection Format  
Serological Test Principle   
EUGENE

 HBsAg: 
The EUGENE

 HBsAg rapid test (Shanghai Eugene Biotech co., Ltd) is a lateral flow immune 
chromatographic assay for the qualitative determination of HBsAg (a marker of HBV infection) 
in human serum or plasma.  
Test Principle 
The EUGENE

 HBsAg rapid test a qualitative immune chromatographic assay employing a 
unique combination of monoclonal dye-conjugate (colloidal gold) and polyclonal solid phase 
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antibodies to selectively identify HBsAg of HBV infection with a high degree of sensitivity. In 
this test, plasma or serum specimen is added directly to the sample pad.  As the test sample flows 
through the sample pad, the labeled antibody-dye conjugate binds to HBsAg forming an 
antibody-antigen complex. The pad is in contact with a chromatographic test strip which contains 
a region of immobilized polyclonal anti-HBsAg antibody in the test line. The antibody-antigen 
complex moves by capillary action along the strip forming a line of immobilized complex by the 
zone of antibody in the test line, indicating the presence of HBsAg in the sample (pink line). If 
no antigen is present, the test line will remain clear. The appearance of a pink line in the control 
line shows that the test has been carried out correctly.   
Test Procedure 
1. Bring the complete kit and sample to be tested to room temperature (15 – 30OC) prior to 
testing.  
2. Remove the test device from its protective pouch, lay it on a dry and clean flat surface, 
and label the device with patient or control number. 
3. Use the dropper or pipette to withdraw serum specimen from the specimen collection 
container and dispense 2 – 3 drops (approximately 80 - 120l) in to the sample well and 
start the timer. 
4. Wait for colored bands to appear. For strong positive, results may be observed within one 
minute. For 5ng/ml, read within 5 – 10 minutes; for 1.5 – 2ng/ml read within 15 – 20 
minutes. However, to confirm negative results, the complete reaction time 20 – 30 
minutes is required. Do not interpret result after 30 minutes.  
 
Interpretation of Results 
Negative: One pink line appears in control line, showing the test has been carried out correctly. 
There will be no line in test region. 
Positive: In addition to a pink colored control line, a distinct pink colored band will also appear 
in the test region. Any shade of color in the test region (T) should be considered positive.  
Invalid: A total absence of color in both regions is an indication of procedure error and/or that 
the test reagent has deteriorated. Repeat the testing using a new device.  
Anti-HCV Rapid Test 
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The EUGENE

 Anti-HCV rapid test (Shanghai Eugene Biotech co., Ltd) is a sandwich lateral 
flow immune chromatographic assay for the qualitative detection of antibodies to HCV in human 
serum or plasma.  
Test Principle  
The EUGENE

 Anti-HCV rapid test is a lateral flow immune chromatographic assay screening 
serum or plasma using recombinant HCV proteins. Recombinant antigens of HCV labeled by 
gold conjugates are used in test band as capture materials, and anti-rabbit HCV antibody is used 
in the control band. When a sample is added in to the sample well of the device, it migrates 
through the membrane strip. If the antibodies to HCV present in the specimen, a complex of 
antibody- gold conjugated recombinant antigens will be formed, which is then captured by 
antigen immobilized in the test zone of the membrane, producing a visible pink color band of 
immune complex conjugate on the membrane. The color intensity will depend on the 
concentration of the ant-HCV present in the sample. Absence of the test band suggests a negative 
result. The test contains an internal control (C band) which should exhibit a pink colored band of 
the immune complex conjugate regardless of color development on the test band. Otherwise, the 
test result is invalid and the specimen must be retested with another device.   
Test Procedure 
1. Bring the complete kit and sample to be tested to room temperature (15 – 30OC) prior to 
testing.  
2. Remove the test device from its protective pouch, lay it on a dry and clean flat surface, 
and label the device with patient or control number. 
3. Hold the dropper vertically and transfer only one drop (about 25l) of serum or plasma to 
the specimen well (S) of the test device, then add two drops (about 100l) of buffer and 
start the timer. 
4. Wait for the red line (s) to appear. The result should be read at 10 – 20 minutes. Do not 
interpret result after 20 minutes.  
Interpretation of Results 
Negative: If only the C band is developed, the test indicates that no detectable antibodies to 
HCV present in the specimen. The result is negative.  
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Positive: If both C and T bands are developed, the test indicates for the presence of antibodies to 
HCV in the specimen. The result is positive. Any shade of color in the test region (T) should be 
considered positive.  
Invalid: If no C band is developed, the assay is in valid regardless of color development on the T 
band. Repeat the assay using a new device. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Laboratory data collection format 
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